Andrew Hutchinson+FollowNew Device Could Change PE TreatmentImperative Care just wrapped up a major study on their Symphony Thrombectomy System, which could totally shake up how doctors treat pulmonary embolism (PE). The device is designed to remove clots more efficiently and safely, and early results look super promising. With the study done across 19 centers, we might be seeing a new standard for PE care soon. Can’t wait to see the results drop later this year! #MedicalInnovation #PulmonaryEmbolism #HealthTech #ClinicalTrials #FutureOfMedicine #Health120Share
Sarah Bennett+FollowBrexit’s Messy Side: Cancer Trials Hit HardBrexit isn’t just about politics—it’s slowing down cancer research in the UK! Since leaving the EU, researchers are dealing with delayed clinical trials, drug import headaches, and even destroyed samples. Cancer Research UK says 80% of scientists are struggling to collaborate with EU partners, and costs are up across the board. Their fix? Less red tape, smoother trade, and better data sharing with Europe. It’s wild how much this impacts real lives and breakthroughs! #BrexitImpact #CancerResearch #ScienceMatters #ClinicalTrials #UKNews #Health00Share
Kristi Key+FollowHigh-Dose Vitamin D Slows MS Onset?Did you know popping high-dose vitamin D might actually slow down early signs of multiple sclerosis? A French study found that people with early MS symptoms who took big doses of vitamin D every two weeks had less disease activity and fewer new brain lesions than those on placebo. It didn’t stop relapses completely, but it did delay things kicking off. Kinda wild that something as simple as vitamin D could make such a difference! #VitaminD #MultipleSclerosis #HealthNews #MSAwareness #ClinicalTrials #Health140Share
Kristi Key+FollowNew Hope for Tough Ovarian Cancer CasesBig news for ovarian cancer research: the FDA just fast-tracked INX-315, a new drug aimed at patients whose tumors resist standard treatments. This CDK2 inhibitor targets a genetic change (CCNE1 amplification) that makes some cancers extra stubborn. Early trials are underway, and if things go well, this could mean a real breakthrough for people running out of options. Fingers crossed for more good news soon! #OvarianCancer #CancerResearch #FDAFastTrack #ClinicalTrials #MedicalBreakthrough #Health70Share
martinezlaura+FollowBreakthrough Molecule for Rare Diseases?Imagine a single molecule that could help treat rare, devastating mitochondrial diseases—no gene editing required! Scientists just found a compound that boosts the cell’s energy factory, even when key DNA is mutated. Early lab tests look super promising, and a human trial is already underway. If this works, it could be a total game-changer for people with these tough-to-treat conditions. Could this be the start of a new era for genetic disease treatment? #ScienceNews #MedicalBreakthrough #Mitochondria #Genetics #ClinicalTrials #Science483Share
nheath+FollowNipocalimab + Vaccines: No Drama!Big news for anyone following new antibody treatments: Nipocalimab, which could help with hemolytic disease in newborns, didn’t mess with how healthy adults responded to routine vaccines in a phase 1 trial. People still got strong immune responses, even though their IgG levels dropped for a bit. Side effects were mostly mild (think: injection site reactions, dizziness), and no serious issues popped up. Looks like this treatment could play nice with your vaccine schedule! #ClinicalTrials #VaccineNews #Nipocalimab #MedicalResearch #HDFN #Health90Share
rachel60+FollowNew Hope for Parkinson’s Symptoms?Just read about this new drug, NLX-112, that’s showing real promise for people with Parkinson’s! In a recent study, folks taking it had fewer movement issues and less dyskinesia from their usual meds, all without major side effects. Even better, it seemed to work well alongside other treatments like amantadine. It’s still early days, but this could be a game-changer for managing Parkinson’s symptoms. Anyone else following this? #ParkinsonsDisease #MedicalBreakthrough #ClinicalTrials #Neurology #HealthNews #Health473Share
Kristi Key+FollowBladder Cancer Breakthrough: 82% CR Rate?!TAR-200 is seriously shaking up the bladder cancer world! In the latest SunRISe-1 study, patients with tough-to-treat bladder cancer saw an insane 82.4% complete response rate—and the results actually lasted, with over half still in remission after a year. Even better, most people handled the treatment well, with only mild side effects for the majority. This could be a game-changer for those out of options! #BladderCancer #MedicalBreakthrough #CancerResearch #TAR200 #ClinicalTrials #Health290Share
